Placebo News and Research

RSS

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

A consortium of researchers led by Monash University will receive more than $3.5 million in Australian Government funding for research into the use of aspirin for reducing heart attacks, strokes and dementia in older Australians.

17 Jan 2005

More data needed on what's effective for hot flashes

A University of Michigan expert on menopause says a new study that indicates placebos work as well as antidepressant drugs to help hot flashes shows how much more research is needed about what gives patients relief.

17 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Amarin Corporation today announced positive data analysis from two exploratory phase IIa clinical studies using Miraxion (formerly referred to as LAX-101c) to treat depression.

12 Jan 2005

Campral, first new treatment for alcoholism in ten years

Forest Laboratories announced that Campral (acamprosate calcium) Delayed- Release Tablets are now available to physicians, patients and pharmacies nationwide.

12 Jan 2005

Modafinil may be a possible medicinal treatment for cocaine dependence

Cocaine dependence is a major public health problem affecting thousands of people around the globe. Despite years of active research there are still no approved medications for the treatment of this life-shattering addiction.

10 Jan 2005

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

InterMune, Inc. today announced that CHEST, the journal of the American College of Chest Physicians, published an important analysis of variables that measure clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), a deadly and debilitating lung disease.

10 Jan 2005

Trial of naproxen and celecoxib suspended

Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.

9 Jan 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Eli Lilly and Company and Boehringer Ingelheim announced today that Cymbalta/Xeristar (duloxetine hydrochloride)(+) has been granted marketing authorization by the European Commission for the treatment of major depressive episodes.

5 Jan 2005

Stem cells from umbilical cord blood effectively treated heart attacks

When injected into rats' hearts soon after a heart attack, stem cells taken from human umbilical cord blood (HUCB) greatly reduced the size of heart damage and restored pumping function to near normal. This improvement occurred without the need for drugs to prevent the rats' immune system from rejecting the human cells.

5 Jan 2005

Laser therapy may be considered by arthritis patients as a safe Vioxx alternative

Adverse events of long term medication with NSAIDs and particularly coxibs, has recently received much attention in the Vioxx matter. Consequently, Vioxx has been withdrawn and Prexige has been withheld from the market. The whole group of coxibs, are now under special observation by drug agencies in both Europe and the United States.

27 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.

21 Dec 2004

FDA issues advice on Naproxen

The FDA has released the following statement on NIH halting a clinical trial involving non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's Disease:

20 Dec 2004

Genzyme files for European approval of Myozyme for treatment of Pompe disease

Genzyme Corp. announced today that the European Medicines Agency (EMEA) has accepted its marketing authorization application for Myozyme(R) (alglucosidase alfa), an investigational enzyme replacement therapy for Pompe disease.

20 Dec 2004

Oral medication alitretinoin effective in treating moderate or severe hand dermatitis

Use of the oral medication alitretinoin was effective in treating moderate or severe hand dermatitis in nearly half of patients previously unresponsive to standard treatment, according to an article in the December issue of The Archives of Dermatology.

20 Dec 2004

Magnetic bracelets reduce pain in osteoarthritis of the hip and knee

Osteoarthritis affects around 760,000 people in the United Kingdom, producing over 3 million general practice consultations in 2000. Manufacturers of magnetic bracelets claim that they can reduce pain and worldwide sales were estimated at £2.6bn ($5bn) in 1999. But evidence about their effectiveness is contradictory.

20 Dec 2004

Placebo News and Research

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

More data needed on what's effective for hot flashes

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Campral, first new treatment for alcoholism in ten years

Modafinil may be a possible medicinal treatment for cocaine dependence

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

Trial of naproxen and celecoxib suspended

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Stem cells from umbilical cord blood effectively treated heart attacks

Laser therapy may be considered by arthritis patients as a safe Vioxx alternative

Public health advisory for the use of non-steroidal anti-inflammatory drug products

Arthritis drug caution advised by New Zealand experts

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

FDA issues advice on Naproxen

Genzyme files for European approval of Myozyme for treatment of Pompe disease

Oral medication alitretinoin effective in treating moderate or severe hand dermatitis

Magnetic bracelets reduce pain in osteoarthritis of the hip and knee

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News